CD8A and neoplasm: Similarly, a vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), initially developed for disrupting tumor vasculature, has also been shown to activate immunostimulatory functions of TAMs, which in turn orchestrate anti-tumor response of CD8+ T cells (218).